Success Metrics

Clinical Success Rate
81.6%

Based on 120 completed trials

Completion Rate
82%(120/147)
Active Trials
30(14%)
Results Posted
63%(76 trials)
Terminated
27(12%)

Phase Distribution

Ph phase_3
20
9%
Ph not_applicable
15
7%
Ph early_phase_1
4
2%
Ph phase_1
57
26%
Ph phase_2
102
47%
Ph phase_4
17
8%

Phase Distribution

61

Early Stage

102

Mid Stage

37

Late Stage

Phase Distribution215 total trials
Early Phase 1First-in-human
4(1.9%)
Phase 1Safety & dosage
57(26.5%)
Phase 2Efficacy & side effects
102(47.4%)
Phase 3Large-scale testing
20(9.3%)
Phase 4Post-market surveillance
17(7.9%)
N/ANon-phased studies
15(7.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.4%

120 of 157 finished

Non-Completion Rate

23.6%

37 ended early

Currently Active

30

trials recruiting

Total Trials

218

all time

Status Distribution
Active(36)
Completed(120)
Terminated(37)
Other(25)

Detailed Status

Completed120
Terminated27
unknown25
Recruiting19
Active, not recruiting11
Withdrawn10

Development Timeline

Analytics

Development Status

Total Trials
218
Active
30
Success Rate
81.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (1.9%)
Phase 157 (26.5%)
Phase 2102 (47.4%)
Phase 320 (9.3%)
Phase 417 (7.9%)
N/A15 (7.0%)

Trials by Status

not_yet_recruiting63%
withdrawn105%
recruiting199%
completed12055%
terminated2712%
active_not_recruiting115%
unknown2511%

Recent Activity

Clinical Trials (218)

Showing 20 of 218 trialsScroll for more
NCT04872595Phase 2

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

Active Not Recruiting
NCT03182244Phase 3

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Active Not Recruiting
NCT00001529

Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Recruiting
NCT01163942Phase 3

Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)

Terminated
NCT03164057Phase 2

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Active Not Recruiting
NCT06528691Phase 2

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Recruiting
NCT02436707Phase 2

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active Not Recruiting
NCT01864109Phase 2

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Active Not Recruiting
NCT05498220Phase 2

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Terminated
NCT01857934Phase 2

Therapy for Children With Advanced Stage Neuroblastoma

Completed
NCT03849651Phase 2

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active Not Recruiting
NCT03250338Phase 3

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Completed
NCT02918292Phase 2

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

Completed
NCT07044544Phase 1

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Recruiting
NCT07441967Phase 2

The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation

Not Yet Recruiting
NCT07428486Phase 1

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Not Yet Recruiting
NCT06207799Phase 2

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Recruiting
NCT03480360Phase 3

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Active Not Recruiting
NCT05561751Phase 2

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Completed
NCT01511562Phase 2

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
218